hLF-HSA

**hLF-HSA** is a recombinant fusion protein comprising human lactoferrin fused to human serum albumin. It was developed as a longer-lived and more cell-internalizable form of lactoferrin with preclinical anticancer and regenerative-medicine potential. In lung cancer cell models, caveolae-mediated uptake of hLF-HSA increases expression and functional activity of sodium/hydrogen exchanger 7, disrupts trans-Golgi-network organelle pH homeostasis through proton leakage, and suppresses cancer-cell proliferation. hLF-HSA has also inhibited migration of lung adenocarcinoma cells, associated with reduced matrix metalloproteinase 1 expression. The asset originated at Tokyo University of Technology and is being advanced by S&K Biopharma. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0006291X24000135))

Other names

human lactoferrin-human serum albumin fusion proteinhuman lactoferrin/human serum albumin fusion proteinhLF-HSA